DGAP-Adhoc: COR&FJA AG: COR&FJA AG signs letter of intent

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
DGAP-Adhoc: COR&FJA AG: COR&FJA AG signs letter of intent for the sale of its plenum shares

COR&FJA AG / Key word(s): Letter of Intent 09.10.2013 13:45 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- COR&FJA AG signs letter of intent for the sale of its plenum shares (Leinfelden-Echterdingen, 9 October 2013) - Today, COR&FJA AG and the Swiss-based company ConQor AG, Zug, signed a letter of intent (LOI) for the planned sale of COR&FJA's shares in plenum AG, Frankfurt am Main (Munich stock exchange: m:access; ISIN DE000A0Z23Y9). The LOI was signed with the agreement of the COR&FJA Supervisory Board. The transaction will be executed subject to a satisfactory due diligence procedure and a final agreement between COR&FJA and ConQor. The purchase price provided for in the LOI is around 1.4 million euros and corresponds to the unweighted average closing price of the plenum share on the last 100 stock-market trading days up until 14 September 2013. COR&FJA currently holds a total of 4,008,825 no-par-value bearer shares in plenum, which corresponds to a 41.33 per cent stake in its nominal capital. The intention within the scope of the planned transaction is that ConQor or a company in the ConQor group should purchase COR&FJA's entire equity stake in plenum. plenum and its subsidiaries are currently being fully consolidated by COR&FJA and, as a result, incorporated into the COR&FJA Group's consolidated financial statements. In the last financial year 2012, the plenum group contributed almost 13.1 million euros of the COR&FJA Group's aggregate sales of 136.7 million euros. In the event of the equity stake in plenum being sold, the plenum group will be deconsolidated with the result that it will no longer contribute to the COR&FJA Group's sales. Issuing party: COR&FJA AG Investor Relations HumboldtstraÃ?e 35, 70771 Leinfelden-Echterdingen Tel. +49 711 94958-0 E-mail: investor.relationsâ??@â??cor.â??fja.com Internet: www.cor.fja.com WKN 513010, ISIN DE0005130108 Stock exchange centres: regulated market in Frankfurt (Prime Standard); open market in Berlin, Düsseldorf, Hamburg, Stuttgart 09.10.2013 DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: COR&FJA AG HumboldtstraÃ?e 35 70771 Leinfelden-Echterdingen Germany Phone: +49 (0)711 94958-0 Fax: +49 (0)711 94958-49 E-mail: investor.relations@cor.fja.com Internet: www.cor.fja.com ISIN: DE0005130108 WKN: 513010 Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, München, Stuttgart End of Announcement DGAP News-Service ---------------------------------------------------------------------------

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

FDA Greenlights Kisqali®: A Major Step for Breast Cancer Care

Updated Category News Views 203

Kisqali® Receives FDA Approval for Early Breast Cancer Treatment Novartis has some exciting news for oncology: the US Food and Drug Administration (FDA) has officially approved Kisqali® (ribociclib) as a treatment for patients diagnosed with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) stage II and III early breast cancer...

Continue Reading
Ålandsbanken Abp Launches SEK 350M Additional Tier 1 Notes Series

Updated Category News Views 162

Ålandsbanken Abp Issues SEK 350,000,000 Additional Tier 1 Notes Ålandsbanken Abp, a prominent player in the banking industry, recently made waves in the financial market by issuing Additional Tier 1 floating rate notes amounting to SEK 350,000,000. The issuance marks a significant step in Ålandsbanken's strategic move to strengthen its capital position and enhance its...

Continue Reading
Harbour BioMed's 2025 Achievements and Future Prospects

Updated Category News Views 249

Harbour BioMed Achieves Significant Milestones in Interim Results Harbour BioMed (HKEX: 02142) is a prominent biopharmaceutical company focused on developing innovative antibody therapeutics, particularly in the fields of immunology and oncology. The company shared its impressive interim results for the first half of the year, showcasing remarkable growth and strategic...

Continue Reading
Innovative Investment Fuels Okika Devices' Future Growth Strategy

Updated Category News Views 187

Strategic Investment Boosts Okika Devices Advancement Colorado ONE Fund, which is part of the ONE Funds initiative, has made a major investment in Okika Devices, a company recognized for its innovation in Field Programmable Analog Array (FPAA) technology. This investment aligns with Colorado ONE Fund's mission to support technologies that advance the local innovation...

Continue Reading
Investors Take Note: Legal Options for Shareholders Explored

Updated Category News Views 61

Exploring Legal Options for Investors in Major Companies In recent developments, Halper Sadeh LLC, a reputable law firm focusing on investor rights, is carefully examining three significant companies for potential violations of federal securities laws. This investigation centers around the actions and decisions made by these firms, which may affect shareholders' rights...

Continue Reading